169 related articles for article (PubMed ID: 38645297)
1. Dalbavancin as an alternative to traditional outpatient parenteral antimicrobial therapy for deep gram-positive infections - an observational, retrospective review.
Bao H; Igwilo-Alaneme R; Sonia F; Cowman K; Kahn M; Nori P
Ther Adv Infect Dis; 2024; 11():20499361241245523. PubMed ID: 38645297
[TBL] [Abstract][Full Text] [Related]
2. The hidden cost of dalbavancin: OPAT RN time required in coordination for persons who use drugs.
Douglass AH; Mayer H; Young K; Sikka MK; Strnad L; Makadia J; Sukerman E; Lewis JS; Streifel AC
Ther Adv Infect Dis; 2023; 10():20499361231189405. PubMed ID: 37581105
[TBL] [Abstract][Full Text] [Related]
3. Dalbavancin Use in Vulnerable Patients Receiving Outpatient Parenteral Antibiotic Therapy for Invasive Gram-Positive Infections.
Bork JT; Heil EL; Berry S; Lopes E; Davé R; Gilliam BL; Amoroso A
Infect Dis Ther; 2019 Jun; 8(2):171-184. PubMed ID: 31054088
[TBL] [Abstract][Full Text] [Related]
4. Experience with dalbavancin use in various gram-positive infections within Aberdeen Royal Infirmary OPAT service.
McSorley JC; Reyes D; Tonna I; Bateman V
Infection; 2024 Apr; 52(2):567-576. PubMed ID: 38165594
[TBL] [Abstract][Full Text] [Related]
5. Dalbavancin vs standard of care for Staphylococcus aureus bacteraemia in patients unable to receive outpatient parenteral antimicrobial therapy.
Frazier JD; Stoudenmire LL; Wagner JL; Thomas GM; Steele GM; Henao-Martínez AF; Franco-Paredes C; Chastain DB
Int J Antimicrob Agents; 2023 Jul; 62(1):106842. PubMed ID: 37160242
[TBL] [Abstract][Full Text] [Related]
6. Dalbavancin in the Treatment of Bacteremia and Endocarditis in People with Barriers to Standard Care.
Ajaka L; Heil E; Schmalzle S
Antibiotics (Basel); 2020 Oct; 9(10):. PubMed ID: 33076275
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Dalbavancin Use on Clinical Outcomes, Cost-Savings, and Adherence at a Large Safety Net Hospital.
Lueking R; Wei W; Mang NS; Ortwine JK; Meisner J
Microbiol Spectr; 2023 Feb; 11(1):e0238522. PubMed ID: 36537818
[TBL] [Abstract][Full Text] [Related]
8. Safety and feasibility of outpatient parenteral antimicrobial therapy for patients with spinal infection.
Kilinc F; Setzer M; Behmanesh B; Jussen D; Gessler F; Keil F; Kempf VAJ; Kessel J; Czabanka M; Prinz V
Sci Rep; 2023 Apr; 13(1):6863. PubMed ID: 37100824
[TBL] [Abstract][Full Text] [Related]
9. Implementation of Outpatient Parenteral Antimicrobial Therapy (OPAT) in Patients with Complicated Periprosthetic Joint Infections.
Strassburg A; Weber AT; Kluba T
Z Orthop Unfall; 2024 May; ():. PubMed ID: 38802072
[TBL] [Abstract][Full Text] [Related]
10. Evaluating the Use of Dalbavancin for Off-Label Indications.
Taylor K; Williamson J; Luther V; Stone T; Johnson J; Gruss Z; Russ-Friedman C; Ohl C; Beardsley J
Infect Dis Rep; 2022 Apr; 14(2):266-272. PubMed ID: 35447884
[TBL] [Abstract][Full Text] [Related]
11. Multicenter clinical experience of real life Dalbavancin use in gram-positive infections.
Wunsch S; Krause R; Valentin T; Prattes J; Janata O; Lenger A; Bellmann-Weiler R; Weiss G; Zollner-Schwetz I
Int J Infect Dis; 2019 Apr; 81():210-214. PubMed ID: 30794940
[TBL] [Abstract][Full Text] [Related]
12. Comparison of dalbavancin to standard-of-care for outpatient treatment of invasive Gram-positive infections.
Veve MP; Patel N; Smith ZA; Yeager SD; Wright LR; Shorman MA
Int J Antimicrob Agents; 2020 Dec; 56(6):106210. PubMed ID: 33223119
[TBL] [Abstract][Full Text] [Related]
13. Dalbavancin Sequential Therapy for Gram-Positive Bloodstream Infection: A Multicenter Observational Study.
Rebold N; Alosaimy S; Pearson JC; Dionne B; Taqi A; Lagnf A; Lucas K; Biagi M; Lombardo N; Eudy J; Anderson DT; Mahoney MV; Kufel WD; D'Antonio JA; Jones BM; Frens JJ; Baumeister T; Geriak M; Sakoulas G; Farmakiotis D; Delaportas D; Larew J; Veve MP; Rybak MJ
Infect Dis Ther; 2024 Mar; 13(3):565-579. PubMed ID: 38427289
[TBL] [Abstract][Full Text] [Related]
14. Acute Bacterial Skin and Skin-Structure Infections, efficacy of Dalbavancin: a systematic review and meta-analysis.
Monteagudo-Martínez N; Solís-García Del Pozo J; Nava E; Ikuta I; Galindo M; Jordán J
Expert Rev Anti Infect Ther; 2022 Nov; 20(11):1477-1489. PubMed ID: 32981375
[TBL] [Abstract][Full Text] [Related]
15. French national cohort of first use of dalbavancin: A high proportion of off-label use.
Dinh A; Duran C; Pavese P; Khatchatourian L; Monnin B; Bleibtreu A; Denis E; Etienne C; Rouanes N; Mahieu R; Bouchand F; Davido B; Lotte R; Cabaret P; Camou F; Chavanet P; Assi A; Limonta S; Lechiche C; Riou R; Courjon J; Illes G; Lacassin-Beller F; Senneville E;
Int J Antimicrob Agents; 2019 Nov; 54(5):668-672. PubMed ID: 31400471
[TBL] [Abstract][Full Text] [Related]
16. Dalbavancin in the treatment of different gram-positive infections: a real-life experience.
Bouza E; Valerio M; Soriano A; Morata L; Carus EG; Rodríguez-González C; Hidalgo-Tenorio MC; Plata A; Muñoz P; Vena A;
Int J Antimicrob Agents; 2018 Apr; 51(4):571-577. PubMed ID: 29180276
[TBL] [Abstract][Full Text] [Related]
17. Effective use of a two-dose regimen of dalbavancin to treat prosthetic joint infections and spinal hardware infections.
Doub JB; Alkayali T; Amoroso A; Nandi S; Talwani R
Eur J Orthop Surg Traumatol; 2023 Dec; 33(8):3655-3659. PubMed ID: 37270761
[TBL] [Abstract][Full Text] [Related]
18. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections.
Seltzer E; Dorr MB; Goldstein BP; Perry M; Dowell JA; Henkel T;
Clin Infect Dis; 2003 Nov; 37(10):1298-303. PubMed ID: 14583862
[TBL] [Abstract][Full Text] [Related]
19. A Dalbavancin for Successful Treatment of Infective Endocarditis Caused by
Teigell-Muñoz FJ; Mateos-González M; Bernal Hertfelder E; Sánchez de Torre A; García-Ferrón M; de Cáceres Velasco C; Bueno Muiño C
Eur J Case Rep Intern Med; 2023; 10(1):003654. PubMed ID: 36819647
[TBL] [Abstract][Full Text] [Related]
20. Off-label use of dalbavancin in children: a case series.
Gamell A; Velasco-Arnaiz E; López-Ramos MG; Ríos-Barnés M; Simó-Nebot S; Fumadó V; Noguera-Julián A; Fortuny C
J Antimicrob Chemother; 2024 Jul; ():. PubMed ID: 38958260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
